エンジェルマン症候群治療薬の世界市場:疫学予測

◆英語タイトル:Angelman Syndrome Epidemiology Forecast to 2030
◆商品コード:DELV20JU174
◆発行会社(リサーチ会社):DelveInsight
◆発行日:2020年7月
◆ページ数:100
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後2営業日)
◆調査対象地域:アメリカ、ヨーロッパ、日本
◆販売価格オプション(消費税別)
Single User(174名様閲覧)USD3,750 ⇒換算¥393,750見積依頼/購入/質問フォーム
Three UserUSD5,625 ⇒換算¥590,625見積依頼/購入/質問フォーム
Site LicenseUSD7,500 ⇒換算¥787,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
DelveInsight社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

DelveInsight’s ‘Angelman Syndrome – Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Angelman Syndrome epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Geographies Covered
The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan
Study Period: 2017–2030
Angelman Syndrome Understanding
The DelveInsight Angelman Syndrome epidemiology report gives a thorough understanding of the Angelman Syndrome by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Angelman Syndrome in the US, Europe, and Japan. The report covers the detailed information of the Angelman Syndrome epidemiology scenario in seven major countries (US, EU5, and Japan).

Angelman Syndrome Epidemiology Perspective by DelveInsight
The Angelman Syndrome epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Angelman Syndrome epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Angelman Syndrome epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Angelman Syndrome Detailed Epidemiology Segmentation
The Angelman Syndrome epidemiology covered in the report provides historical as well as forecasted Angelman Syndrome epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

The DelveInsight Angelman Syndrome report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report
The Angelman Syndrome report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
The Angelman Syndrome Epidemiology Report and Model provide an overview of the global trends of Angelman Syndrome in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
The report provides insight into the historical and forecasted patient pool of Angelman Syndrome in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
The report helps recognize the growth opportunities in the 7MM for the patient population
The report assesses the disease risk and burden and highlights the unmet needs of Angelman Syndrome
The report provides the segmentation of the Angelman Syndrome epidemiology
Report Highlights
11-year Forecast of Angelman Syndrome epidemiology
7MM Coverage
Prevalent and Diagnosed Cases of Angelman Syndrome
Cases of Angelman Syndrome by Mutation Types
Angelman Syndrome Cases associated with Clinical Manifestations
KOL views
We interview, KOLs and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered
What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Angelman Syndrome?
What are the key findings pertaining to the Angelman Syndrome epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017–2030)?
What would be the total number of patients of Angelman Syndrome across the 7MM during the forecast period (2017–2030)?
Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017–2030)?
At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017–2030)?
What is the disease risk, burden and unmet needs of Angelman Syndrome?
What are the currently available treatments of Angelman Syndrome?
Reasons to buy
The Angelman Syndrome Epidemiology report will allow the user to -

Develop business strategies by understanding the trends shaping and driving the global Angelman Syndrome market
Quantify patient populations in the global Angelman Syndrome market to improve product design, pricing, and launch plans
Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Angelman Syndrome therapeutics in each of the markets covered
Understand the magnitude of Angelman Syndrome population by its epidemiology
The Angelman Syndrome Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources
Key Assessments
Patient Segmentation
Disease Risk & Burden
Risk of disease by the segmentation
Factors driving growth in a specific patient population

【レポートの目次】

1. Key Insights

2. Executive Summary of Angelman Syndrome

3. SWOT Analysis for Angelman Syndrome

4. Disease Background and Overview

4.1. Introduction

4.2. Cause

4.3. Signs and Symptoms

4.4. Related Disorders and Differential Diagnosis

4.5. Complications

4.6. Genetics of Angelman syndrome

4.7. Molecular Genetic Pathogenesis

4.8. Diagnosis

4.9. Clinical criteria for diagnosis

4.10. Disease History and Medical Conditions

4.11. Diagnostic Algorithm

5. Epidemiology and Patient Population

5.1. Key Findings

5.2. 7MM Total Prevalent Patient Population of Angelman syndrome

6. Country Wise-Epidemiology of Angelman syndrome

6.1. The United States

6.1.1. Assumptions and Rationale

6.1.2. Total Prevalent Cases of Angelman Syndrome in the United States

6.1.3. Diagnosed Prevalent Cases of Angelman Syndrome in the United States

6.1.4. Angelman Syndrome cases by Mutation Types in the United States

6.1.5. Angelman Syndrome associated with Clinical Manifestations in the United States

6.2. EU5

6.2.1. Assumptions and Rationale

6.2.1.1. Germany

6.2.1.2. Total Prevalent Cases of Angelman Syndrome in Germany

6.2.1.3. Diagnosed Prevalent Cases of Angelman Syndrome in Germany

6.2.1.4. Angelman Syndrome cases by Mutation Types in Germany

6.2.1.5. Angelman Syndrome associated with Clinical Manifestations in Germany

6.2.2. France

6.2.2.1. Total Prevalent Cases of Angelman Syndrome in France

6.2.2.2. Diagnosed Prevalent Cases of Angelman Syndrome in France

6.2.2.3. Angelman Syndrome cases by Mutation Types in France

6.2.2.4. Angelman Syndrome associated with Clinical Manifestations in France

6.2.3. Italy

6.2.3.1. Total Prevalent Cases of Angelman Syndrome in Italy

6.2.3.2. Diagnosed Prevalent Cases of Angelman Syndrome in Italy

6.2.3.3. Angelman Syndrome cases by Mutation Types in Italy

6.2.3.4. Angelman Syndrome associated with Clinical Manifestations in Italy

6.2.4. Spain

6.2.4.1. Total Prevalent Cases of Angelman Syndrome in Spain

6.2.4.2. Diagnosed Prevalent Cases of Angelman Syndrome in Spain

6.2.4.3. Angelman Syndrome cases by Mutation Types in Spain

6.2.4.4. Angelman Syndrome associated with Clinical Manifestations in Spain

6.2.5. The United Kingdom

6.2.5.1. Total Prevalent Cases of Angelman Syndrome in the United Kingdom

6.2.5.2. Diagnosed Prevalent Cases of Angelman Syndrome in the United Kingdom

6.2.5.3. Angelman Syndrome cases by Mutation Types in the UK

6.2.5.4. Angelman Syndrome associated with Clinical Manifestations in the UK

6.3. Japan

6.3.1. Assumptions and Rationale

6.3.2. Total Prevalent Cases of Angelman Syndrome in Japan

6.3.3. Diagnosed Prevalent Cases of Angelman Syndrome in Japan

6.3.4. Angelman Syndrome cases by Mutation Types in Japan

6.3.5. Angelman Syndrome associated with Clinical Manifestations in Japan

7. Treatment and Management of Angelman syndrome

7.1. Recommendations for the management of Angelman Syndrome

7.2. Future treatment options for Angelman Syndrome

7.2.1. Gene Therapy

7.2.2. Topoisomerase Inhibitors

7.2.3. Minocycline

7.2.4. Cannabidiol (CBD)

7.2.5. Protein Phosphatase 2A (PP2A) Inhibitor

8. Unmet Needs

9. Organizations contributing toward Angelman Syndrome

10. KOL’s Views: Angelman Syndrome

11. Patient Journey

12. Journey toward a Diagnosis: Diagnosing a Rare form of Angelman Syndrome

13. Case Reports

13.1. A Case of Fundus Oculi Albinoticus Diagnosed as Angelman Syndrome by Genetic Testing – A Japanese Case Study

13.2. Two Angelman families with unusually advanced neurodevelopment carry a start codon variant in the most highly expressed UBE3A isoform: a case report of US

13.3. Angelman Syndrome: A Case Series Assessing Neurological Issues in Adulthood– A European Case Report

14. Appendix

15.Report Methodology

16. DelveInsight Capabilities

17. Disclaimer

18. About DelveInsight

Table 1: Summary of Angelman Syndrome Market, Epidemiology, and Key Events (2017–2030)

Table 2: Genetic mechanisms giving rise to Angelman syndrome

Table 3: Molecular genetic testing used in AS after DNA methylation analysis

Table 4: Prevalent Patient Population of Angelman Syndrome in 7MM (2017–2030)

Table 5: Total Prevalent Cases of Angelman Syndrome in the United States (2017–2030)

Table 6: Diagnosed Prevalent Cases of Angelman Syndrome in the United States (2017–2030)

Table 7: Angelman Syndrome cases by Mutation Types in the United States (2017–2030)

Table 8: Angelman Syndrome associated with Clinical Manifestations in the United States (2017–2030)

Table 9: Total Prevalent Cases of Angelman Syndrome in Germany (2017–2030)

Table 10: Diagnosed Prevalent Cases of Angelman Syndrome in Germany (2017–2030)

Table 11: Angelman Syndrome cases by Mutation Types in Germany (2017–2030)

Table 12: Angelman Syndrome associated with Clinical Manifestations in Germany (2017–2030)

Table 13: Total Prevalent Cases of Angelman Syndrome in France (2017–2030)

Table 14: Diagnosed Prevalent Cases of Angelman Syndrome in France (2017–2030)

Table 15: Angelman Syndrome cases by Mutation Types in France (2017–2030)

Table 16: Angelman Syndrome associated with Clinical Manifestations in France (2017–2030)

Table 17: Total Prevalent Cases of Angelman Syndrome in Italy (2017–2030)

Table 18: Diagnosed Prevalent Cases of Angelman Syndrome in Italy (2017–2030)

Table 19: Angelman Syndrome cases by Mutation Types in Italy (2017–2030)

Table 20: Angelman Syndrome associated with Clinical Manifestations in Italy (2017–2030)

Table 21: Total Prevalent Cases of Angelman Syndrome in Spain (2017–2030)

Table 22: Diagnosed Prevalent Cases of Angelman Syndrome in Spain (2017–2030)

Table 23: Angelman Syndrome cases by Mutation Types in Spain (2017–2030)

Table 24: Angelman Syndrome associated with Clinical Manifestations in Spain (2017–2030)

Table 25: Total Prevalent Cases of Angelman Syndrome in the United Kingdom (2017–2030)

Table 26: Diagnosed Prevalent Cases of Angelman Syndrome in the United Kingdom (2017–2030)

Table 27: Angelman Syndrome cases by Mutation Types in the UK (2017–2030)

Table 28: Angelman Syndrome associated with Clinical Manifestations in the UK (2017–2030)

Table 29: Total Prevalent Cases of Angelman Syndrome in Japan (2017–2030)

Table 30: Diagnosed Prevalent Cases of Angelman Syndrome in Japan (2017–2030)

Table 31: Angelman Syndrome cases by Mutation Types in Japan (2017–2030)

Table 32: Angelman Syndrome associated with Clinical Manifestations in Japan (2017–2030)

Table 33: Feeding and Diet Recommendations

Table 34: Development Recommendations

Table 35: Seizure Types—the following are typical of AS:

Table 36: Treatment for Seizures and CNS

Table 37: Recommendations for the management of Angelman Syndrome

Table 38: Recommendations for the management of Vision & Hearing

Table 39: Recommendations for the management of Behavior

Table 40: Recommendations for the management of Speech and Communication

Table 41: Recommendations for the management of Dental Issues and Drooling

Table 42: General health and Anesthesia Recommendations

Table 43: Scoliosis and Skeletal Recommendations

Table 44: Puberty and Sexual Health Recommendations

Table 45: Organizations contributing to Angelman syndrome

List of Figures

 Figure 1: SWOT Analysis

Figure 2: Imprinting map of Paternal and Maternal human Chromosome 15q11-13 around AS-1C

Figure 3: Imprinting map of Paternal and Maternal human Chromosome 15q11-13 around AS-1C

Figure 4: Imprinting map of Paternal and Maternal human Chromosome 15q11-13 around AS-1C

Figure 5: Diagnostic Algorithm

Figure 6: Prevalent Patient Population of Angelman Syndrome in 7MM (2017–2030)

Figure 7: Total Prevalent Cases of Angelman Syndrome in the United States (2017–2030)

Figure 8: Diagnosed Prevalent Cases of Angelman Syndrome in the United States (2017–2030)

Figure 9: Angelman Syndrome cases by Mutation Types in the United States (2017–2030)

Figure 10: Angelman Syndrome associated Clinical Manifestations in the United States (2017–2030)

Figure 11: Total Prevalent Cases of Angelman Syndrome in Germany (2017–2030)

Figure 12: Diagnosed Prevalent Cases of Angelman Syndrome in Germany (2017–2030)

Figure 13: Angelman Syndrome cases by Mutation Types in Germany (2017–2030)

Figure 14: Angelman Syndrome associated Clinical Manifestations in Germany (2017–2030)

Figure 15: Total Prevalent Cases of Angelman Syndrome in France (2017–2030)

Figure 16: Diagnosed Prevalent Cases of Angelman Syndrome in France (2017–2030)

Figure 17: Angelman Syndrome cases by Mutation Types in France (2017–2030)

Figure 18: Angelman Syndrome associated Clinical Manifestations in France (2017–2030)

Figure 19: Total Prevalent Cases of Angelman Syndrome in Italy (2017–2030)

Figure 20: Diagnosed Prevalent Cases of Angelman Syndrome in Italy (2017–2030)

Figure 21: Angelman Syndrome cases by Mutation Types in Italy (2017–2030)

Figure 22: Angelman Syndrome associated Clinical Manifestations in Italy (2017–2030)

Figure 23: Total Prevalent Cases of Angelman Syndrome in Spain (2017–2030)

Figure 24: Diagnosed Prevalent Cases of Angelman Syndrome in Spain (2017–2030)

Figure 25: Angelman Syndrome cases by Mutation Types in Spain (2017–2030)

Figure 26: Angelman Syndrome associated Clinical Manifestations in Spain (2017–2030)

Figure 27: Total Prevalent Cases of Angelman Syndrome in the United Kingdom (2017–2030)

Figure 28: Diagnosed Prevalent Cases of Angelman Syndrome in the United Kingdom (2017–2030)

Figure 29: Angelman Syndrome cases by Mutation Types in the UK (2017–2030)

Figure 30: Angelman Syndrome associated Clinical Manifestations in the UK (2017–2030)

Figure 31: Total Prevalent Cases of Angelman Syndrome in Japan (2017–2030)

Figure 32: Diagnosed Prevalent Cases of Angelman Syndrome in Japan (2017–2030)

Figure 33: Angelman Syndrome cases by Mutation Types in Japan (2017–2030)

Figure 34: Angelman Syndrome associated Clinical Manifestations in Japan (2017–2030)

Figure 35: Unmet Needs of Angelman syndrome


【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[エンジェルマン症候群治療薬の世界市場:疫学予測]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆